ANIK
Anika Therapeutics Inc
NASDAQ: ANIK · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$12.39
-18.81% today
Updated 2026-04-29
Market cap
$165.66M
P/E ratio
—
P/S ratio
1.47x
EPS (TTM)
$-0.79
Dividend yield
—
52W range
$8 – $16
Volume
0.1M
Anika Therapeutics Inc (ANIK) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-9.64%
Operating margin
2.11%
ROE
-6.71%
ROA
-3.52%
Debt/equity
0.17x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $26.84M | $4.60M | 58.58% | 20.22% | 17.15% |
| 2007 | $30.83M | $6.04M | 61.46% | 21.37% | 19.58% |
| 2008 | $35.78M | $3.63M | 63.14% | 11.81% | 10.14% |
| 2009 | $40.14M | $3.69M | 65.94% | 13.92% | 9.19% |
| 2010 | $55.56M | $4.32M | 57.11% | 13.57% | 7.77% |
| 2011 | $64.78M | $8.47M | 58.65% | 21.56% | 13.07% |
| 2012 | $71.36M | $11.76M | 59.38% | 27.63% | 16.48% |
| 2013 | $75.08M | $20.57M | 69.68% | 43.43% | 27.40% |
| 2014 | $105.59M | $38.32M | 80.18% | 58.19% | 36.29% |
| 2015 | $93.00M | $30.76M | 77.36% | 51.76% | 33.07% |
| 2016 | $103.38M | $32.55M | 76.76% | 48.95% | 31.48% |
| 2017 | $113.42M | $31.82M | 75.87% | 40.32% | 28.05% |
| 2018 | $105.56M | $18.72M | 70.37% | 20.60% | 17.74% |
| 2019 | $114.61M | $27.19M | 74.92% | 29.88% | 23.73% |
| 2020 | $130.46M | $-23.98M | 52.91% | -21.71% | -18.38% |
| 2021 | $147.79M | $4.13M | 56.12% | 1.77% | 2.80% |
| 2022 | $156.24M | $-14.86M | 59.89% | -12.42% | -9.51% |
| 2023 | $120.79M | $-82.67M | 68.33% | 0.70% | -68.44% |
| 2024 | $119.91M | $-56.38M | 63.38% | -4.25% | -47.02% |
| 2025 | $112.82M | $-10.88M | 56.56% | -9.80% | -9.64% |